Et al Phillip Frost MD - 05 Aug 2026 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: COCP
Reported as of: 05 Aug 2026
Net transaction value: +$9,816
SEC form: 4
Accepted by SEC: 06 Aug 2026, 17:11:40 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Phillip Frost, MD ET AL

Key filing fact

Et al Phillip Frost MD filed Form 4 for Cocrystal Pharma, Inc. (COCP) on 06 Aug 2026.

Key facts

This page summarizes Et al Phillip Frost MD's Form 4 filing for Cocrystal Pharma, Inc. (COCP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Aug 2026, 17:11.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: +$9,816.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000898860 Primary reporting owner

FROST PHILLIP MD ET AL

Relationship: Director, 10%+ Owner
Address: 4400 BISCAYNE BLVD, MIAMI
Signature: /s/ Phillip Frost, MD ET AL
Signature date: 06 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COCP transaction

Common Stock

Purchase

Transaction value: $9,816
Shares: +10,000
Change %: +0.5%
Price: $0.9816
Shares after: 1,993,551
Date: 05 Aug 2026
Ownership: By Frost Gamma Investments Trust
Footnotes: F1, F2

COCP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 27,100
Date: 05 Aug 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.972 to $0.9898, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence.

Footnote F2

These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Footnote F3

Includes shares of common stock issuable upon vesting of restricted stock units.

SEC remarks

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.